Dr. Reddy's Laboratories' IFRS net income for fiscal year 2022 was ₹23.568 billion, up 36.7% from ₹17.238 billion the previous year. Revenue increased 13% to ₹214.391 billion compared to ₹189.722 billion a year earlier.

Dr. Reddy's is selling to Binnopharm Group, part of Sistema, the right to sell Ciprolet and Levolet antibacterial drugs in Russia, Belarus and Uzbekistan. At the initial stage Dr. Reddy's will supply the drugs to the Russian company, and in the future their production will be localized at the facilities of Binnopharm Group. The terms of the deal were not dis...

Dr. Reddy's Laboratories IFRS net income for 9 months of fiscal 2022 was ₹22.693 billion, up 66.7% from ₹13.614 billion in the previous year. Revenue rose 12.3% to ₹160.023 billion compared to ₹142.438 billion a year earlier.

Indian drug maker Dr. Reddy's Laboratories will release a generic of molnupiravir, a tablet from Merck's COVID-19. The drug will be sold under the brand name Molflu. The total cost of a 5-day course of treatment, consisting of 40 capsules, will be ₹1,400, or $18.77, while the original Merck pills cost $700. Molflu sales across India are scheduled to begin ne...